These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 26915654)

  • 1. Can botox improve night-time overactive bladder symptoms in women?
    Miotla P; Cartwright R; Futyma K; Bogusiewicz M; Skorupska K; Winkler I; Rechberger T
    Neurourol Urodyn; 2017 Mar; 36(3):648-652. PubMed ID: 26915654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery.
    Miotla P; Futyma K; Cartwright R; Bogusiewicz M; Skorupska K; Markut-Miotla E; Rechberger T
    Int Urogynecol J; 2016 Mar; 27(3):393-8. PubMed ID: 26364180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
    Jiang YH; Kuo HC
    Neurourol Urodyn; 2017 Feb; 36(2):338-343. PubMed ID: 26575613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB.
    Miotla P; Cartwright R; Skorupska K; Bogusiewicz M; Markut-Miotla E; Futyma K; Rechberger T
    Neurourol Urodyn; 2017 Aug; 36(6):1564-1569. PubMed ID: 27701762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
    Miotla P; Cartwright R; Skorupska K; Bogusiewicz M; Markut-Miotla E; Futyma K; Rechberger T
    Int Urogynecol J; 2017 Jun; 28(6):845-850. PubMed ID: 27889830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
    Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders.
    Khusid JA; Weiss JP; Carlsson MO; Mangan EK
    J Urol; 2017 Nov; 198(5):1119-1123. PubMed ID: 28479240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
    Balzarro M; Rubilotta E; Braga A; Bassi S; Processali T; Artibani W; Serati M
    Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():228-231. PubMed ID: 29753213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
    Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
    Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study.
    Liao CH; Chen SF; Kuo HC
    Neurourol Urodyn; 2016 Aug; 35(6):717-23. PubMed ID: 25914349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
    Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
    Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of fesoterodine on nocturia and quality of sleep in Asian patients with overactive bladder.
    Yokoyama O; Hiro S; Hotta S; Mogami S; Yamagami H
    Urology; 2014 Apr; 83(4):750-5. PubMed ID: 24518285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolterodine treatment of women with overactive bladder syndrome: Comparison of night-time and daytime dosing for nocturia.
    Tsai KH; Hsiao SM; Lin HH
    J Obstet Gynaecol Res; 2017 Nov; 43(11):1719-1725. PubMed ID: 28714288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
    Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
    Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.